Europe Biosimulation Market Report and Forecast 2024-2032

Europe Biosimulation Market Outlook

The global biosimulation market size was valued at USD 3.5 billion in 2023, with Europe holding a significant market share. The market is driven by technological advancements in biosimulation platforms and tools. It is expected to grow at a CAGR of 16.90% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.

Key Takeaways

• Recent data suggests that 25% of all annual cancer cases occur in Europe, with nearly half of the population at risk of developing cancer at some point in their lives . The rising emphasis on accelerating oncology drug development, fuelled by the growing number of cancer cases, is expected to surge market demand.

• One of the major Europe biosimulation market trends is the increased collaborative initiatives among the key market players to utilize biosimulation platforms in clinical applications. In March 2024, Exploristics and Exonate Ltd announced a successful collaboration involving the optimisation of clinical trial designs for Exonate’s upcoming Phase IIb study by leveraging Exploristics’ KerusCloud (a simulation-guided study design platform).

• In March 2023, Certara, Inc., announced the launch of Simcyp™ PBPK Simulator Version 22, adding novel and updating existing features of its population-based modeling and simulation platform. The launch of such technologically advanced biosimulation systems is likely to elevate market value.

Europe Biosimulation Market Analysis

Biosimulation is a comparatively newer tool in pharmaceutical drug development that enables researchers to simulate complex biological systems. Several leading market players are actively integrating biosimulation software in their drug development pipelines, owing to its ability to predict drug behavior, optimize treatment strategies, and reduce costs and time compared to conventional experiments. Thus, the rising adoption of biosimulation platforms by pharmaceutical and biotechnology companies is significantly contributing to the Europe biosimulation market growth.

Biosimulation can prove helpful in predicting the long-term outcomes of therapies for chronic diseases including cancer. In Europe, with rising prevalence of cancer, predictive models are increasingly utilized to develop effective treatments. Recent data suggests that 25% of all annual cancer cases occur in the region, with nearly half of the population in Europe at risk of developing cancer at some point in their lives (the cumulative risk estimated to be 49.3%). The rising emphasis on accelerating oncology drug development, fuelled by the growing number of cancer cases in the region, is expected to surge the Europe biosimulation market demand.

Increased collaborative initiatives among the prominent market players facilitate the sharing of resources and expertise, enabling the translation of biosimulation research into clinical applications. In March 2024, Exploristics (a United Kingdom-based provider of bio-simulation software and biostatistics services) and Exonate Ltd (a pharmaceutical company in England) announced a successful collaboration involving optimizing the clinical trial design for Exonate’s upcoming Phase IIb study by leveraging Exploristics’ KerusCloud (a simulation-guided study design platform). The companies were able to establish an enhanced study design for Exonate’s lead candidate, EXN407, an investigational topical treatment for retinal vascular diseases, by using KerusCloud. The increased application of such simulation platforms to reduce risks, cost, and duration associated with a clinical study is likely to boost the Europe biosimulation market share in the forecast period.

Technological advancements in biosimulation software enable more accurate predictions of complex biological processes, such as drug metabolism and pharmacodynamics. Continuous improvement and innovation in the existing biosimulation models is poised to fuel market growth. In March 2023, Certara, Inc., a global leader in drug discovery and development through biosimulation technology, announced the launch of Simcyp™ PBPK Simulator Version 22, adding novel and updating existing features of its population-based modeling and simulation platform. The new pharmacokinetics (PBPK) platform has expanded capabilities for a diverse range of populations and therapeutics types, thereby advancing the drug development process. The release of such innovative biosimulation platforms supported by substantial investments from pharmaceutical companies is anticipated to elevate the market value in coming years.

Europe Biosimulation Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

Europe Biosimulation Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Dassault Systèmes

• Schrödinger

• Physiomics Plc

• Simulations Plus

• Insilico Biotechnology

• Genedata

• Argenx

• CureVac SE

• INOSIM Software GmbH

• Certara

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Europe Biostimulation Market Report Snapshots

Europe Biostimulation Market Size

Europe Biostimulation Market Analysis

Europe Biostimulation Companies